Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders

NCT06990529 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT06990529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06990529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 29, 2025
Completion date
August 12, 2029
Enrollment
12 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pids linked to pi3k